DESTINY-Breast03 Phase 3 Study Results
Best Change in Target Lesions (All Patients)
100.
T-DXd (n = 348)
100
DESTINY-Breast04
Daiichi-Sankyo
TPC (n = 156)
Best % Change in Sum of Diameters From Baseline
-100
-60
-40.
-20
20.
40.
*
60
60
80
80
*17
-80.
IHC 1+
IHC 2+/ISH-
***
****
***
*****
*
80
60
60
40
40
*
20
20
0
-20
-40
-60
**
**
-80
IHC 1+
IHC 2+/ISH-
-100
****
*
*
*Patients with HR- disease
Shown are the best percentage changes from baseline in the sum of the largest diameters of measurable tumors in patients for whom data from both baseline and postbaseline assessments of target lesions by independent central review
were available. The upper dashed horizontal line indicates a 20% increase in tumor size in the patients who had disease progression, and the lower dashed line indicates a 30% decrease in tumor size (partial response).
HR, hormone receptor; IHC, immunohistochemistry; ISH, in situ hybridization; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
ASCO 2022 #LBA3 Plenary Session
17View entire presentation